C5 and hemolytic-uremic syndrome: The aim of this review is to provide a pragmatic approach to intensivists about when to investigate for complement dysregulation with specialized alternative complement analysis in critically ill patients harbouring thrombotic microangiopathy (TMA) features, how to cautiously interpret these results, and to discuss when to consider anti-C5 therapy in patients with HUS who have been admitted to emergency or intensive care units.